Autocatalytic phosphorylation of FGFR2c mutants with enhanced ligand binding

Stable Identifier
R-HSA-2033486
Type
Reaction [transition]
Species
Homo sapiens
Compartment
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

After aberrantly dimerizing in response to mesenchymally expressed ligands, FGFR2c S252W and P253R mutants are assumed to undergo transautophosphorylation analagous to the wild-type receptor, although this has not been explicitly demonstrated. Knock-down or chemical inhibition of other FGFR2-activating mutations identified in endometrial cancer cells has been shown to cause cell death (Byron, 2008).

Literature References
PubMed ID Title Journal Year
18757403 Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation

Byron, SA, Gartside, MG, Wellens, CL, Mallon, MA, Keenan, JB, Powell, MA, Goodfellow, PJ, Pollock, PM

Cancer Res 2008
Participants
Participant Of
Catalyst Activity
Catalyst Activity
Title
protein tyrosine kinase activity of FGFR2c mutant dimers with enhanced ligand-binding bound to FGFs [plasma membrane]
Physical Entity
Activity
Disease
Name Identifier Synonyms
ovarian cancer 2394 ovarian neoplasm, malignant tumour of ovary, neoplasm of ovary (disorder), ovary neoplasm, primary malignant neoplasm of ovary and other uterine adnexa (disorder), ovarian cancer, tumor of the Ovary, ovary cancer, malignant Ovarian tumor, primary ovarian cancer, malignant tumor of ovary (disorder)
female reproductive endometrioid cancer 3001 endometrioid tumor (morphologic abnormality), endometrioid neoplasm
cancer 162 malignant tumor, malignant neoplasm, primary cancer
bone development disease 0080006
Authored
Reviewed
Created
Cite Us!